We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > imdevimab

News List

US FDA grants EUA to Regeneron’s antibody cocktail for Covid-19 pharmaceutical-technology
November 23, 2020
The US Food and Drug Administration (FDA) has granted Emergency Use Authorisation (EUA) to Regeneron Pharmaceuticals’ antibody cocktail casirivimab and imdevimab for treating patients with mild to moderate Covid-19.
US FDA grants EUA to monoclonal antibodies from Regeneron for COVID-19 treatment expresspharma
November 23, 2020
In a clinical trial, casirivimab and imdevimab, administered together, were shown to reduce COVID-19-related hospitalisation or emergency room visits in patients at high risk for disease progression within 28 days after treatment.

Previous page 1 2 Next page